Exelixis reported Q4 2022 financial results, with total revenues of $423.9 million and a GAAP diluted EPS of $(0.09). The company continued to advance its cabozantinib franchise and pipeline through clinical data readouts and new collaborations.
Total revenues for Q4 2022 were $423.9 million, compared to $451.1 million for the comparable period in 2021.
Net product revenues for Q4 2022 were $377.4 million, compared to $302.7 million for the comparable period in 2021.
GAAP net loss for Q4 2022 was $(30.2) million, or $(0.09) per share, basic and diluted, compared to GAAP net income of $95.2 million, or $0.29 per share diluted, for the comparable period in 2021.
Non-GAAP net loss for Q4 2022 was $(10.2) million, or $(0.03) per share, basic and diluted, compared to non-GAAP net income of $113.3 million, or $0.35 per share, diluted, for the comparable period in 2021.
Exelixis is maintaining its financial guidance for fiscal year 2023.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance